Astel­las pres­i­dent jumps to a new Fron­tier; Gri­fols chair­man named CEO, break­ing fam­i­ly tra­di­tion

→ An­drew Krivoshik has jumped ship at Astel­las to be­come CMO at Fron­tier Med­i­cines, a sub­stan­tial get for Chris Var­ma and his pre­ci­sion med­i­cines crew fo­cused on un­drug­gables. Krivoshik joined Astel­las from Ab­bott in 2011 and was the on­col­o­gy ther­a­peu­tic area head at the Japan­ese phar­ma when the Seagen-part­nered an­ti­body-drug con­ju­gate Pad­cev notched a full FDA ap­proval in 2021.

Since then, Krivoshik as­cend­ed to SVP and head of de­vel­op­ment ther­a­peu­tic ar­eas, and then pres­i­dent and head of de­vel­op­ment in April 2022. Ab­b­Vie paid $55 mil­lion up­front in a De­cem­ber 2020 pro­tein degra­da­tion pact with Fron­tier, which wants to chal­lenge Am­gen and Mi­rati in the KRAS space.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER